Repatha market forecast points to faster growth in Asia-Pacific

The Business Research Company says the Repatha market is set to expand through 2035, driven by rising cardiovascular disease, high cholesterol and obesity rates. North America led in 2025, but Asia-Pacific is projected to grow fastest as demand builds for biologic lipid-lowering therapies.

Why it matters: - The Repatha market is tied to rising demand for advanced cholesterol-lowering treatment as cardiovascular disease and high LDL cholesterol cases increase worldwide. - Growth in this market could expand access to PCSK9 inhibitor therapy for patients who do not reach cholesterol targets with diet or statins alone. - The trend matters for preventive cardiology because Repatha is positioned as a long-term option to reduce cardiovascular risk.

What happened: - The Business Research Company published its Repatha Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Repatha market has grown on the back of more hyperlipidemia cases, limits of statin-only treatment, more diagnoses of familial hypercholesterolemia, wider specialized cardiovascular care and more biologic lipid-lowering therapies. - The report also says the market is expected to benefit from demand for advanced cardiovascular solutions, broader combination lipid management, preventive cardiology, personalized cholesterol control and more investment in biologic drug development. - The report names broader PCSK9 inhibitor adoption, more injectable lipid-lowering drugs, stronger cardiovascular risk reduction, expansion of biologic cholesterol treatments and longer-term lipid management as key forecast trends. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Repatha is evolocumab, a monoclonal antibody used to lower cholesterol in patients with hyperlipidemia. - Repatha blocks PCSK9, a protein that reduces the liver’s ability to clear LDL cholesterol from the bloodstream. - The drug is typically used when diet or statin therapy does not bring cholesterol to target levels. - Rising cardiovascular disease is a major demand driver because lowering LDL cholesterol can reduce the risk of major cardiovascular events. - The British Heart Foundation reported in September 2024 that about 7.6 million people in the UK have heart and circulatory diseases. - The British Heart Foundation projected that number would rise by 1 million by 2030 and by another 2 million by 2040. - BioMed Central reported in August 2025 that global prevalence stood at 28.8% for hypertriglyceridemia, 24.1% for hypercholesterolemia, 38.4% for low HDL cholesterol and 18.93% for high LDL cholesterol. - BioMed Central said men were more likely to have hypertriglyceridemia, while women had higher rates of low HDL cholesterol. - OECD data published in November 2025 showed obesity prevalence across member countries rising from 13% to 19% on average. - The report includes Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional outlook. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, and key technology and future trend analysis. - The release includes a free sample report and a full market report.

Between the lines: - The report frames Repatha’s growth as part of a broader shift toward biologic and injectable lipid management, not just traditional statin-based care. - The combination of aging populations, rising obesity and persistent cholesterol disorders suggests demand could stay elevated even if treatment guidelines change slowly. - Asia-Pacific’s growth outlook likely reflects expanding diagnosis and treatment access rather than the market’s current size leadership.

What's next: - The market is expected to keep expanding through 2035 as cardiovascular risk management becomes more personalized and biologic therapies gain broader use. - Future adoption will likely depend on how quickly health systems move toward combination lipid-lowering strategies and longer-term prevention care. - The report points to continued regional divergence, with North America remaining a major market and Asia-Pacific delivering the fastest growth.